EGFR is a transmembrane receptor tyrosine kinase protein that is expressed in some normal epithelial, mesenchymal, and neurogenic tissue. Overexpression of EGFR has been reported and implicated in the pathogenesis of many human malignancies, including NSCLC.
Epidemiology Insights included in the report
- Total incident population of NSCLC in 7MM was 484,726 in 2017
- The incident cases of EGFR mutation in the United States in 2017 was 37,370
- The incident population of EGFR-NSCLC in the United States contributed around 34% of the total population of EGFR mutated NSCLC in the 7MM in 2017
- Among the EU5 countries, Germany had the highest incident population of NSCLC and that was 29%
Scope of the EGFR Market Report
• The report covers the descriptive overview of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• Comprehensive insight has been provided into the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Outlook
According to DelveInsight, Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017–2030. The therapeutic market of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer in seven major markets was found to be USD 1,893 million in 2017 which is expected to increase during study period (2017–2030).
The United States Market Outlook
In 2017, the total market size of EGFR-NSCLC therapies was found to be USD 1,150 million in the United States which is expected to increase in the study period (2017–2030).
EU-5 Countries: Market Outlook
In 2017, the total market size of EGFR-NSCLC therapies was found to be USD 536 million in the EU-5 countries which is expected to increase in the study period (2017–2030).
Japan Market Outlook
The total market size of EGFR-NSCLC therapies in Japan was found to be USD 208 million in 2017.
Table of contents
1. Key Insights
2. Executive Summary of EGFR-NSCLC
3. SWOT Analysis of EGFR-NSCLC
4. EGFR-NSCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of EGFR-NSCLC in 2017: By Country
4.2. Total Market Share (%) Distribution of EGFR-NSCLC in 2030: By Country
5. EGFR-Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Cellular Classification of NSCLC
5.1.2. Signs and Symptoms of NSCLC
5.1.3. Risk Factors of Lung Cancer
5.1.4. Causes of NSCLC
5.1.5. Disease Biology: NSCLC
6. Diagnosis of NSCLC
6.1. Diagnostic Algorithm for NSCLC
6.2. Stages of NSCLC
6.3. Staging System
7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Incident cases of NSCLC patients in the 7MM
7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Incident cases of NSCLC patients in the United States
7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
7.4.4. Total EGFR NSCLC cases in the United States
7.4.5. Total EGFR NSCLC Treated patient Pool in the United States
8. EU-5 Epidemiology
8.1. Germany
8.1.1. Total Incident cases of NSCLC patients in Germany
8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
8.1.4. Total EGFR NSCLC cases in Germany
8.1.5. Total EGFR NSCLC Treated patient Pool in Germany
8.2. France
8.2.1. Total Incident cases of NSCLC patients in France
8.2.2. Total Incident cases of NSCLC patients by Histology in France
8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
8.2.4. Total EGFR NSCLC cases in France
8.2.5. Total EGFR NSCLC Treated patient Pool in France
8.3. Italy
8.3.1. Total Incident cases of NSCLC patients in Italy
8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
8.3.4. Total EGFR NSCLC cases in Italy
8.3.5. Total EGFR NSCLC Treated patient Pool in Italy
8.4. Spain
8.4.1. Total Incident cases of NSCLC patients in Spain
8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
8.4.4. Total EGFR NSCLC cases in Spain
8.4.5. Total EGFR NSCLC Treated patient Pool in Spain
8.5. The United Kingdom
8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
8.5.4. Total EGFR NSCLC cases in the United Kingdom
8.5.5. Total EGFR NSCLC Treated patient Pool in the United Kingdom
9. Japan Epidemiology
9.1. Japan
9.1.1. Total Incident cases of NSCLC patients in Japan
9.1.2. Total Incident cases of NSCLC patients by Histology in Japan
9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
9.1.4. Total EGFR NSCLC cases in Japan
9.1.5. Total EGFR NSCLC Treated patient Pool in Japan
10. Current Treatment Practices: NSCLC
10.1. Advanced/Metastatic NSCLC Treatment Algorithm
10.2. Chemotherapy
10.3. Targeted Therapy
10.4. Immunotherapy
10.5. Surgery
10.6. Radiation Therapy
10.7. Stage-wise Treatment Options of NSCLC
11. Guideline of NSCLC
11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020
11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018
11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018
12. Unmet Needs of EGFR NSCLC
13. Key Endpoints in EGFR NSCLC Clinical Trials
14. Marketed Therapies
14.1. Key Cross
14.2. Tagrisso(Osimertinib): AstraZeneca
14.2.1. Product Description
14.2.2. Regulatory Milestones
14.2.3. Other Developmental Activities
14.2.4. Pivotal Clinical Trials
14.2.5. Ongoing Current Pipeline Activity
14.3. Vizimpro (Dacomitinib): Pfizer
14.3.1. Product Description
14.3.2. Regulatory Milestones
14.3.3. Other Developmental Activities
14.3.4. Pivotal Clinical Trials
14.3.5. Ongoing Current Pipeline Activity
15. Emerging Therapies
15.1. Nazartinib (EGF816): Novartis Pharmaceuticals
15.1.1. Product Description
15.1.2. Clinical Development
15.1.3. Safety and Efficacy
15.2. Capmatinib (INC280): Novartis Pharmaceuticals
15.2.1. Product Description
15.2.2. Other Development Activities
15.2.3. Clinical Development
15.2.4. Safety and Efficacy
15.3. JNJ-61186372 (JNJ-6372): Janssen Research & Development
15.3.1. Product Description
15.3.2. Other Development Activity
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.4. Lazertinib: Yuhan Corporation/ Janssen Research & Development
15.4.1. Product Description
15.4.2. Clinical Development
15.4.3. Safety and Efficacy
15.5. TAK-788: Takeda
15.5.1. Product Description
15.5.2. Clinical Development
15.5.3. Safety and Efficacy
16. EGFR-Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
17. EGFR Mutation—Market Size
17.1. Total Market Size of EGFR-positive NSCLC in the 7MM
17.2. Market Size of EGFR-positive NSCLC by Therapeutic Class in the 7MM
17.3. United States Market Size
17.4. EU-5 Market Size
17.4.1. Germany Market Size
17.4.2. France Market Size
17.4.3. Italy Market Size
17.4.4. Spain Market Size
17.4.5. United Kingdom Market Size
17.5. Japan Market Size
18. Market Access and Reimbursement of NSCLC Therapies
19. Market Drivers of NSCLC
20. Market Barriers of NSCLC
21. Appendix
21.1. Bibliography
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/